13F Holdings
中文EN

DYAI DYADIC INTERNATIONAL INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1213809 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-7.6%
TTM net income YoY4.7%
TTM EPS YoY13.0%
Revenue 3-yr CAGR1.5%
Net income 3-yr CAGR—

Margins

Gross margin17.9%
Operating margin-236.7%
Net margin-226.9%
FCF margin—
EBITDA margin—

Returns

ROE-47,256.0%
ROA-71.4%
ROIC (approx.)—
Asset turnover0.31x

Leverage & solvency

Liabilities / assets132.5%
Debt / equity—
Current ratio1.69x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.00x
Accruals ratio0.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$3.09M$3.50M$2.90M$2.93M$2.40M
Cost of revenue$2.32M$1.19M$1.98M$2.12M$1.94M
Gross profit$770,485$2.30M$922,957$807,110$459,393
R&D expense$2.15M$2.04M$3.30M$4.50M$8.39M
SG&A expense$5.76M$6.13M$5.82M$6.42M$6.70M
Operating income-$7.19M-$5.90M-$8.23M-$10.17M-$14.73M
Pretax income-$7.33M-$5.76M-$6.77M-$9.83M-$13.12M
Income tax————$0
Net income-$7.36M-$5.81M-$6.80M-$9.74M-$13.07M
EPS (basic)-0.23-0.20-0.24-0.34-0.47
EPS (diluted)-0.23-0.20——-0.47
Weighted avg. shares (diluted)32.62M29.32M——27.84M
Balance sheet
Cash & equivalents$4.62M$6.51M$6.52M$5.79M$15.75M
Short-term investments$2.70M$2.76M———
Receivables$1.09M$237,027$466,159$330,001$277,831
Current assets$9.90M$9.83M$8.07M$13.42M$21.01M
Total assets$9.95M$9.93M$8.22M$13.71M$21.30M
Current liabilities$3.69M$2.45M$2.25M$2.45M$2.56M
Total liabilities$8.71M$7.46M$2.34M$2.63M$2.91M
Shareholders' equity$1.23M$2.47M$5.88M$11.09M$18.39M
Shares outstanding36.19M29.84M28.81M28.56M28.23M
Cash flow statement
Operating cash flow-$5.70M-$3.97M-$6.73M-$8.08M-$11.28M
Investing cash flow$82,085-$1.88M$7.45M-$2.37M$5.22M
Financing cash flow$4.96M$5.85M$0$543,591$1.23M
Stock-based compensation$930,183$1.13M$1.24M$1.89M$1.78M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.